Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire - Archive ouverte HAL Access content directly
Journal Articles Bulletin du Cancer Year : 2020

Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire


Ovarian cancers express highly immunogenic tissue-specific antigens. The resulting immune infiltration is a major prognostic factor. There is therefore a strong biological rationale for the development of immunotherapy in ovarian cancer. However, based on Phase I and II clinical trials data, the efficacy of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (ICPIs) remains limited in monotherapy in heavily pre-treated patients. Currently, the identification of predictive biomarkers of response and resistance is one of the major areas of research. Identifying effective combination of anti-PD-1 or anti-PD-L1 with other anticancer agents is another clinical need. Several combinations were evaluated. The association of ICPIs with chemotherapy (anthracyclines or carboplatin+paclitaxel) is disappointing (JAVELIN studies). The association with PARP inhibitors, anti-angiogenic agents and CTLA-4 inhibitors seems promising. Other immune therapies such as cell therapies (adoptive transfer of intra-tumor lymphocytes, CAR T cells or vaccines from dendritic cells) could be the future of immunotherapy in ovarian cancer but only early phase studies clinical data is available at this time.
Fichier principal
Vignette du fichier
S0007455120300369.pdf (443.22 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03490307 , version 1 (20-05-2022)


Attribution - NonCommercial - CC BY 4.0



Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, Magali Terme, Eric Tartour, et al.. Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire. Bulletin du Cancer, 2020, 107, pp.465 - 473. ⟨10.1016/j.bulcan.2019.11.015⟩. ⟨hal-03490307⟩
56 View
43 Download



Gmail Facebook Twitter LinkedIn More